Optimal rule-based general A+B designs in phase I clinical trials
Contemporary Clinical Trials · 2026-11 · 170 · 108488
DOI: 10.1016/j.cct.2026.108488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026-11. Verfasst von Jingxia Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health Sciences, Dept. of Surgery, Washington University School of Medicine, St Louis, MO 63110, United States of America; Institu…. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Research Design. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Lin et al. studied the statistical properties of rule-based general A+B designs using true toxicity probabilities, without and with dose de-escalation, and derived exact formulae for key statistical quantities essential for phase I clinical trials. METHODS: We systematically evaluate the impact of the parameters of A, B, C, D and E on the key statistical quantities across five dose levels within the A+B=6 framework. Simulation studies are conducted with true toxicity probabilities generated using a dose-toxicity model on known prior toxicity probabilities. RESULTS: General A+B designs with dose de-escalation are more conservative than those without dose de-escalation. For either presence or absence of dose de-escalation, 1) under an under-toxic environment, the 33222 design is the best design and 24113 design is the second one, but 33222 design requires two more patients expected to be treated than 24113 design. 2) under moderate-toxic and over-toxic environments, 24113 and 42111 designs demonstrate absolute and evident superiority, respectively. 3) under an uncertain-toxic environment, 33122 design is the optimal choice but requires a larger total number of patients expected to be treated. 4) under an over-/uncertain-toxic environment, the traditional "3+3" is one of the top two designs with the smallest total numbers of patients expected to be treated and patients experiencing a dose-limiting toxicity. CONCLUSIONS: Some general A+B designs have superior performance to traditional "3+3" design, having the target toxicity level closest to target toxicity rate (TTR) and higher number of patients treated at the dose levels with toxicity probabilities close to TTR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Public Health Sciences, Dept. of Surgery, Washington University School of Medicine, St Louis, MO 63110, United States of America; Institute for Informatics, Data Science & Biostatistics, Washington Universit…
- Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St Louis, MO 63110, United States of America.
Förderung
- Foundation for the National Institutes of Health
Zitieren
APA
Liu, J., & Xie, T. (2026). Optimal rule-based general A+B designs in phase I clinical trials. Contemporary Clinical Trials, 170, 108488. https://doi.org/10.1016/j.cct.2026.108488
Vancouver
Liu J, Xie T. Optimal rule-based general A+B designs in phase I clinical trials. Contemporary Clinical Trials. 2026;170:108488. doi:10.1016/j.cct.2026.108488
BibTeX
@article{Liu2026,
author = {Liu, Jingxia and Xie, Tianxin},
title = {Optimal rule-based general A+B designs in phase I clinical trials},
journal = {Contemporary Clinical Trials},
year = {2026},
volume = {170},
pages = {108488},
doi = {10.1016/j.cct.2026.108488}
}
EUVIMED